(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Why Cannes Is the Ultimate New Year’s Eve Destination in the South of France’s Off-Season - 25 Most Expected Film Delivery
- 3A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- 4Top Breakfast Food: What's Your Morning Enjoyment?
- 5Everyday Seasonal Positions That Compensate Fairly in the US
- At least 36 dead in major fire in Hong Kong residential blocks
- 4 Family SUVs: Joining Solace and Style
- Analysis-NASA's moon mission tests aerospace old guard as SpaceX, Blue Origin hover
- Qantas and Virgin Australia Ban Power Bank Usage on Flights Following Safety Incidents
- India's top court hears challenges to ruling on women's entry into temple
- Most loved Web-based feature: Which Stage Do You Like
- Holiday destinations for Creature Sweethearts
- Understanding climate change in America: Skepticism, dogmatism and personal experience
- Manual for Famous Beverages 2024
